Effect of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Effect of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis ; volume:14 ; number:1 ; day:25 ; month:1 ; year:2024 ; pages:1-9 ; date:12.2024
Scientific reports ; 14, Heft 1 (25.1.2024), 1-9, 12.2024
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-52331-w
- URN
-
urn:nbn:de:101:1-2024040513290619443117
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 08:54 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sayour, Alex Ali
- Oláh, Attila
- Ruppert, Mihály
- Barta, Bálint András
- Merkely, Béla
- Radovits, Tamás
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Direct cardiac effects of SGLT2 inhibitors
Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
SGLT2-Inhibitoren – Effektive Blutzuckerregulation über die Niere
Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors
Class effects of SGLT2 inhibitors on cardiorenal outcomes
SGLT2-inhibitors; more than just glycosuria and diuresis
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Direct cardiac effects of SGLT2 inhibitors
Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
SGLT2-Inhibitoren – Effektive Blutzuckerregulation über die Niere
Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors
Class effects of SGLT2 inhibitors on cardiorenal outcomes
SGLT2-inhibitors; more than just glycosuria and diuresis
Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
Direct cardiac effects of SGLT2 inhibitors
Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
SGLT2-Inhibitoren – Effektive Blutzuckerregulation über die Niere
Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors
Class effects of SGLT2 inhibitors on cardiorenal outcomes